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Abstract 
Background: The use of artemisinin-based combination therapy (ACT) as first-line treatment for uncomplicated 
malaria was a policy recommended by World Health Organization. In 2004, Ghana changed her first-line anti-malarial 
drug policy to use ACT. This study examined factors affecting adverse events reporting in northern Ghana after the 
introduction of ACT.
Methods: This was a qualitative study based on sixty in-depth interviews with health workers, chemical shop owners 
and patients with malaria who were given ACT at the health facilities. Purposive sampling method was used to select 
study participants. The interviews were transcribed, coded into themes using Nvivo 9 software. The thematic analysis 
framework was used to analyse the data.
Results: Study respondents reported body weakness and dizziness as the most frequent side effects they had expe-
rienced from the used of ACT. Other side effects they reported were swollen testes, abdominal pain and shivering. 
These side effects were mostly associated with the use of artesunate-amodiaquine compared to other artemisinin-
based combinations. Patients were not provided information about the side effects of the drugs and so did not report 
when they experienced them. Also long queues at health facilities and unfriendly health worker attitude were the 
main factors affecting adverse events reporting. Other factors such as wrong use of ACT at home, farming and com-
mercial activities also affected effective adverse events reporting in the study area.
Conclusion: Patients’ lack of knowledge and health sector drawbacks affected side effect reporting on ACT. Inten-
sive health education on likely side effects of ACT should be provided to patients by health workers. Also, improving 
health worker attitude toward clients will encourage patients to visit the health facilities when they react negatively to 
ACT and, subsequently, will improve on adverse events reporting.
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Background
The World Health Organization (WHO) in 2001 rec-
ommended to all malaria endemic countries to shift to 
artemisinin-based combination therapy (ACT) for the 
management of uncomplicated falciparum malaria [1]. 
Due to the urgency of the policy change, most health 
systems embraced the new policy without a proper 
understanding of the appropriateness of the different 
formulations of ACT for their contexts. The choice of 
an ACT was based primarily on available literature with 
limited trials in-country to determine their efficacy, cost 
effectiveness and the capacity of local industry to pro-
duce generic drugs [2, 3]. Consequently, research studies 
that evaluated the performance of the new anti-malarials 
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reported widespread severe side effects such as severe 
headache, body weakness, dizziness and vomiting [4, 5]. 
Patients who experienced side effects were required to 
report to the nearest health facility, but compliance was 
low due to poor adverse events reporting systems [4]. An 
adverse event is any undesirable experience associated 
with the use of a medical product in a patient [6]. Patients 
with mild side effects were able to contain them at home 
and severe cases reported to health facilities. Although 
most of the causes of the side effects were drug-related, 
some were due to the introduction of generics that were 
poorly formulated and poor compliance to drug regi-
mens [4].
Ghana changed her first-line anti-malarial drug pol-
icy in 2004, from chloroquine to the use of artesunate-
amodiaquine as the first-line drug for the treatment 
of uncomplicated malaria [7]. The implementation 
process was faced with several challenges related to 
adverse events and lack of other treatment options [7]. 
Artemether-lumefantrine and dihydroartemisinin-pipe-
raquine were subsequently added as first-line anti-malar-
ial treatment for uncomplicated malaria to cater for those 
who could not tolerate the artesunate-amodiaqiune [7].
These different artemisinin-based combinations have 
been used to treat uncomplicated malaria in Ghana for 
about a decade now. However, surveillance on adverse 
events has not been encouraging. Data on adverse events 
of ACT has not been systematically collected and, there-
fore, little evidence exists in determining the effective-
ness of the drugs in real life situations. This study was 
designed to explore the factors that influence adverse 
events reporting in two rural districts in northern Ghana. 
Specifically, the study obtained information on the 
adverse events of ACT, examined how the information is 
obtained from patients and makes recommendations for 




This study was conducted in the Kassena Nankana east 
and west Districts. The study area covers about 1675 
square kilometres of Sahelian savannah with a population 
of about 153,000 under continuous demographic sur-
veillance [8]. The area is predominantly rural with sub-
sistence farming as the mainstay for the people. Malaria 
burden is seasonal with the high transmission period 
occurring between June–October coinciding with the 
rainy season [9, 10].
The health system in the area comprises one hospital, 
eight health centres/clinics, two private clinics and 28 
Community-based Health Planning and Services (CHPS) 
compounds located in the communities and providing 
limited curative and preventive services [11, 12]. The 
district hospital located in Navrongo central serves as a 
referral hospital for all the health facilities operating in 
the two districts. There is one pharmacy shop and over 
50 drug and chemical shops located in the study districts.
Sampling of health facilities
The study area is divided into five zones (North, South, 
East, West and Central) based on their geographical loca-
tions by the NHDSS [8]. Based on these demarcations, 
two zones were randomly selected for the study. This was 
done by writing the names of the five zones on a piece 
of paper each and concealed by wrapping the paper. 
Two people randomly selected the first two zones which 
were north and south. The two health centres located in 
the two selected zones were used for the recruitment of 
study participants. The Government of Ghana launched 
the National health Insurance Scheme (NHIS) in 2004 
to replace user fees or what is popularly known as “cash 
and carry” [13]. The health insurance scheme has ten 
accredited chemical shops in the study area. The only two 
accredited chemical shops located in the selected zones 
were also used as recruitment centres. In addition, the 
district hospital and the only pharmacy shop located in 
Navrongo town were also selected as recruitment sites 
for study participants due to their high patronage for 
malaria treatment in the districts.
Sampling of respondents
All malaria patients who visited the study health facilities 
and received ACT during the period of data collection in 
the selected health facilities were recruited into the study. 
The data collectors spent 2  days in each of the selected 
health facilities/chemical shops and all patients with 
malaria who received ACT were identified and followed-
up for interview at home. All qualified patients consented 
to be part of the study. The longest duration for taking 
ACT is 3 days. All recruited participants were therefore 
followed-up on the 4th day when they were expected to 
have completed their doses. Health workers/chemical 
shop owners in the study health facilities/chemical shops 
in the two zones were also selected for the in-depth inter-
views. The health professionals were selected to share 
their experiences on the side effects of ACT and the fac-
tors affecting side effects reporting.
Data collection
The in-depth interviews were conducted by trained uni-
versity graduates with experience in qualitative research 
technique. Addresses were obtained from study partici-
pants who were recruited at the study facilities to enable 
the data collectors visit them at home and conduct the 
interviews. Appointments were booked with all the study 
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participants before the interviews were conducted. A 
total of sixty in-depth interviews were conducted in this 
study. Twenty interviews with health professionals and 
forty interviews with patients with malaria who were 
given ACT at the study facilities. The interviews were 
tape recorded with consent from participants. The inter-
views were conducted in Kasem, Nankani and English 
depending on the language the participant preferred.
Data processing and analysis
The recorded interviews were transcribed verbatim and 
entered into a computer using Microsoft word. A cod-
ing list was prepared based on the objectives of the study. 
The transcripts were read and edited to make sure that 
all themes were covered during data collection. The data 
analysis was initiated simultaneously with data collec-
tion. This was to ensure that new emerging themes were 
incorporated into the guide and that thematic saturation 
was monitored. The data was organized using QSR Nvivo 
9 software before analysis. A codebook was developed 
based on the major themes of the study. Quotes from the 
interviews were used to support themes discussed in the 
results.
Ethical consideration
Ethical approval for the study was received from the 
Navrongo Health Research Centre Institutional Review 
Board. The approval number is NHRCIRB 152. In line 
with the approved procedure of obtaining consent for 
the study, oral consent was obtained from each partici-
pant prior to being interviewed and this was approved as 
part of the protocol for this study. Oral informed consent 
was obtained because the study processes posed minimal 
risk to study participants. This method of consent was 
solicited and obtained as the majority of the respondents 
had no formal education and those with formal educa-
tion also opted for this method of consent. The verbal 
consent was voice recorded with the agreement of par-
ticipants preceding to each interview. The data collectors 
read and translated the consent form into the preferred 
local language of each participant on the purpose of the 
study, study procedure, right to withdraw and efforts to 
ensure confidentiality. The oral consenting process was 
recorded on a separate voice recorder from the one used 
for the actual interview. In addition, they were made to 
recommend a member of the household to witness the 
consenting process and the demographic data of the wit-
nesses were collected. Participants were also told that the 
findings would be published in a peer review journal. All 
children from 10 to 17 years old gave assent while their 




The findings revealed that participants who took artesu-
nate-amodiaqiune to treat malaria reported most side 
effects. The most commonly reported side effects were 
general body weakness and dizziness. Participants asso-
ciated poor eating before taking their medications as the 
main cause of the side effects. Others however thought 
that the components of artesunate-amodiaqiune were 
too high for them and, therefore, the side effects. Some 
patients shared their experiences in the excerpts below.
“I was given artesunate-amodiaquine and when 
I started taking the drug I could not do anything 
because my whole body was weak” (IDI: 29-year old 
male patient).
The other side effects reported were vomiting, chest 
pains, itching, loss of appetite, poor vision and shiver-
ing. Some participants said they experienced an unu-
sual heart beat and their health deteriorated after taking 
artesunate-amodiaquine.
“….When I took the artesunate-amodiaquine, I had 
chest pains and I vomited” (IDI: 32-year old female 
patient).
Other uncommon side effects of ACT were also 
reported by one of the participants. As she put it:
“.…others especially the men have their testes and 
body swollen. We got this experience from our 
father who died of malaria” (IDI: 32-year old female 
patient).
Similar views were shared by health professionals and 
chemical shop owners on the side effects patients with 
malaria experience from using ACT. A 38-year old health 
worker had this to say on the issue:
“Well, some patients vomit and there is dizziness as 
well, but it is the dizziness and the vomiting that I 
have heard a lot of people complained about. Some 
people complain of poor vision and difficulty to hear 
or they experience some noise in their ears”(IDI: 
38-year old health worker).
The health workers explained that some malaria patients 
only initiate treatment when the condition is severe and 
that this was responsible for some of the side effects and 
not necessarily ACT. They were particularly concerned 
about overdosing of medications, including ACT, by some 
patients as a contributor to these side effects.
“The other reason is that they think that when they 
take overdose it will help to cure the illness fast and 
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this makes them get the side effect. Those who are 
insured, when they collect these drugs they go and 
share them with those who are not insured at home 
and such people will not be able to educate them the 
way they will take the drug hence they can use the 
drug the way they want and when they get these side 
effects, they turn to put the blame on the drug” (IDI: 
32-year old health worker).
Table  1 contains summary of reported side effects of 
artesunate-amodiaquine by study participants.
Consultation content during out‑patient visits
The consultation content between clinician and client in 
the Out-Patient Department (OPD) focused mainly on 
drug administration to the neglect of drug efficacy and 
side effects. Only a few patients reported receiving infor-
mation on side effects of the ACT that was given but none 
reported being told to report back to the health facility if 
they experienced any side effects. They said that providers 
emphasized on the drug regimen and occasionally shared 
information on prevention methods for malaria.
“They did not tell me anything apart from the way 
I should use the medicine. This is my second time of 
going there (health facility) and they have not told 
me anything on the side effects I will get when I use 
the drug” (IDI: 25-year old female patient).
The providers confirmed that in addition to giving 
instructions on the dosing regimen, they are required 
to provide information on side effects to patients and to 
explain to them why it was important for them to report 
any side effects they experience with the drug to the 
nearest health facility. They however said that they rarely 
share such information with their clients due to the high 
patient numbers that characterize the OPDs daily. This 
was clearly conveyed by one of the health workers in the 
following quote:
“Yes, as for that one, it is true, some don’t have the 
time to do the education and I think it is Out Patient 
Department (OPD) congestion that is causing that. 
Sometimes the OPDs will be too full with patients 
seeking for health care services that you think if I 
should waste time doing education, I cannot finish 
early. I think that is the reason because all of us have 
been trained on the counseling but we are not doing 
because of the pressure on us” (IDI: 26-year old 
health worker).
Adverse events reporting system
According to the health workers, reporting of adverse 
drug events within the health system is spontaneous. 
Health workers solicit the events from their clients with 
the expectation that the clients will comply. All reported 
events are captured using a specially designed form from 
the Ghana Food and Drugs Authority (FDA). Pharma-
cists at the various health facilities have the primary 
responsibility of collating all reported events, which are 
then forwarded to the FDA office within the region for 
advice. The FDA is required to examine the report and 
feedback to the health facility for any follow up visits to 
the patients. A 46-year old pharmacist shared his views 
this way on the issue:
“Yes there is a procedure and what usually happens 
is that there is an institutional contact person that 
is the pharmacist, who is supposed to compile all the 
side effects people come to complain about. There is a 
form that you are to record all these complaints which 
will be forwarded to Food and Drug Authority (FDA) 
at the national level for their study and advice. After 
that the report is sent back to the institution for their 
study and action based on the advice offered by FDA. 
There are various possibilities that can cause a person 
to react to medication. It could be wrong usage, the 
Table 1 Reported side effects of Artesunate-Amodiaquine
Side effect Quote
Body weakness “I was given artesunate-amodiaquine and when I started taking the drug I could not do anything because my whole body was 
weak” (IDI-29 year old male patient)
Vomiting and dizziness “Well, some patients vomit and there is dizziness as well, but it is the dizziness and the vomiting that I have heard a lot of people 
complained about. Some people complain of poor vision and difficulty to hear or they experience some noise in their ears” (IDI-
38 year old health worker)
Chest pains “…When I took the artesunate-amodiaquine, I had chest pains and I vomited” (IDI-32 year old female patient)
Swollen testicles “…others especially the men have their testes and body swollen. We got this experience from our father who died of malaria. When 
it starts unless he takes akpetashie (type of wine prepared locally) (type of wine prepared locally) it will always be serious” (IDI-
32 year old female patient)
Loss of appetite “When my child took the artesunate-amodiaquine, he was weak and could not open his eyes. For me, immediately I put it into my 
mouth, I become very weak… when I took it the first time, I lost appetite and I was also very weak” (IDI-26 year old Mother).
Shivering and poor vision “Some people complain of poor vision and difficulty to hear or they hear some noise in their ears” (IDI-36 year old health worker)
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human system, combination of different drugs at the 
same time among others. So we have to monitor the 
person and make sure that he/she takes the drug cor-
rectly and if the same side effects are presented then 
you have to change treatment for the person and see” 
(IDI: 46-year old pharmacist).
Factors affecting adverse events reporting
Provider and patient-related factors were the two broad 
factors identified to be responsible for the low reports of 
adverse drug reactions in the study area.
Provider‑related factors
The providers reported that, doctors, pharmacists and 
dispensary technicians who are required to educate 
patients on adverse drug events are few and the pressure 
of work leaves them no time to discharge such duties. 
The absence of qualified human resource to serve the 
high number of patients has made some of the facilities 
to settle for less qualified technicians who do not have 
the capacity to provide such education. Also, at the com-
munity level, community members are not routinely told 
during sensitization programmes or at the dispensary 
level to report adverse events.
‘That is the issue, usually, they are supposed to be 
told about it either at the OPD level or at the dispen-
sary when they are issued with the medications. The 
problem is that it doesn’t normally happen because 
we do not even have qualified staff at the dispensary 
to do the education. The language is also a problem 
and I remember when I was at Sandema, because of 
the language barrier, I could not communicate with 
the patients. Quite apart from that we do not have 
enough staff at the dispensary and that is also a fac-
tor because the few people who are there are usu-
ally under pressure to serve patients and as a result, 
there is no time to be able to educate patients on all 
these issues (IDI: 42-year old Pharmacist).’
Lack of awareness of their responsibility when adverse 
events occur was the main reason for not reporting 
to health facilities according to the patients who were 
interviewed.
“Many of them (refers to health workers) do not 
give that information to us. Instead of them to tell 
you that when you take the drug and get side effects, 
you should come back to complain they don’t do 
that. They will just give you the drugs and ask you 
to go and take and that is all. If they were to tell you 
that when you take the drug you will get this or that 
problem and when it happens like that you should 
come back to the hospital, they don’t do that” (IDI: 
38-year old male patient).
“Because they have not asked me to come back; let’s 
say if the doctor gives you the drug and tells you to 
come back when you get some disturbances after you 
have taken the drug then you have to go back but if 
the doctor does not tell you to come back you will 
not go. Actually, they have never given me a drug 
and ask me to come back if I take the drug and get 
some disturbances with the drug” (IDI: 42-year old 
female patient).
The patients attributed the low reporting to the unpro-
fessional conduct of some health workers which deterred 
patients from returning to report adverse events. Health 
professionals were reported to be verbally abusive and 
patients did not find it pleasant to have encounters with 
them unless it was absolutely necessary. A female patient 
had this to say:
“Yeah at times when you go back to the health facil-
ity, they would shout at you and say that is the way 
the drug works; that is the way the drug works and 
if you don’t want them to shout at you then you will 
not go back and tell them and rather prefer to keep 
it. So when you go for the first time and they shout at 
you that way, when you take it again and it happens 
like that you will not go?” (IDI: 31-year old female 
patient).
Fear of abuse also prevented patients who sought treat-
ment outside health facilities from reporting adverse 
events. The participants reported that this was common 
with patients who suffered side effects due to non-adher-
ence to the dosing regimen because they were likely to 
be verbally abused by the health workers. This is how a 
female patient expressed her concerns.
“The reason is that some people usually do not have 
money to go to the hospital and would usually go 
and buy cheap drugs at the drugstore. The problem 
is that when they take the drugs wrongly and get 
problems (side effects) at home, they are afraid to go 
and tell the doctor because they do not know what 
the doctor would say and sometime, they could be 
insulted by these health workers. This is the one other 
reason why such people who get these side effects do 
not report”(IDI: 26-year old female patient).
Patient‑related factors
Patients are usually not motivated to come back and 
report adverse events especially if the side effects are those 
already known to be associated with the drug. Patients 
perceived such side effects as normal and reporting them 
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held no relevance to them. Patients preferred to endure 
such side effects at home rather than report them to the 
health facility with the reason that every drug has a side 
effect and therefore it was normal to experience them.
“The reason is that I know the way it works and that 
made me not to go back and I was waiting to see what 
would happen after the third day….So because I know 
how the drug works is the reason why I did not go 
back to tell them” (IDI: 30-year old female patient).
Participants also identified long queues at the OPD that 
led to long waiting-time before receiving care as a criti-
cal factor that affect the reporting of adverse events. To 
them, such experiences were not worth repeating just 
to report an adverse event. Patients preferred to spend 
time on their farms than to traveling to health facilities to 
report adverse events.
“It is because of the long queues at the health facili-
ties where we usually have to go and spend the whole 
day before seeing the doctor makes it difficult for us 
to go back when we get some of these problems after 
using the drugs” (IDI: 29-year old female patient).
“…you know most of the women here are business 
women and some of them are farmers,. So if they 
have the side-effects and they can still walk they 
will prefer to go to their farms and work rather than 
coming to the facility. And others will say that if I 
am strong enough to go to the facility why don’t I just 
go to the market and manage my business, so mostly 
that is the reason why they don’t come” (IDI: 29-year 
old health worker).
Other patients said that previous reports of side effects 
yielded no benefits to them. They were therefore not 
motivated to report subsequent events because they did 
not see the relevance of the exercise. Peers who heard 
their stories were not also motivated to report their own 
experience with ACT to the facilities.
“You know when I went and complained to them 
they did not do anything about it, they rather said 
it is the drug and it would go. Now that they said it 
is as a result of the drug and nothing else why then 
would you waste your time going if you take the drug 
again and get these side effects. When I talk about it 
for other people to know, they will not also go back to 
the health facility when they take the drug and expe-
rience those things because they know it is the drug 
that is working” (IDI: 44-year old female patents).
Suggestions on how to improve adverse events reporting
Various suggestions were given by participants to help 
improve on adverse events reporting. Most of the 
patients were of the view that health education should 
be given to patients in order to encourage them to report 
these side effects.
“…drug store attendants and the health workers at 
the hospitals should often inform patients of the pos-
sible side effects and also tell them to come back if 
they experience serious side effects after taking the 
drugs so that they can test you and see what the 
problem is”(IDI: 38-year old female patient).
The health workers said that most people were igno-
rance and at such did not know that they were supposed 
to come back and report and if patients were reminded 
continuously each time they were given ACT, it would 
have a positive impact on adverse event reporting in the 
study area.
“…we (health workers) should have patience towards 
our clients and try to educate them about the side 
effects and also encourage them to report when they 
get these side effects at home….” (IDI: 41-year old 
health worker).
Most of the patients said that it was important for 
health workers to have patience and behave nicely toward 
their clients in a manner that would encourage them to 
always feel free to visit the health facility anytime they 
have health problems. Patients were of the opinion that 
there should be a policy whereby people who took ACT 
and got side effects should not be made to join long 
queues at the hospital during review visits.
“The nurses should have patience when dealing with 
people at the health facility. They should tell the peo-
ple to feel free and come back to the health facility 
anything they take these drugs and get side effects….” 
(IDI: 25-year old female patient).
“…The doctors should make it such that when you 
take the drugs and get side effects you should walk 
straight to the doctor and complain to him, it should 
not look like you are coming for the first time where 
you would go and follow line for long before you 
see the doctor to give your complain about the side 
effects you got from using the drugs they gave you” 
(IDI: 39-year old female patient).
Limitations
Though, this study provides information on factors affect-
ing adverse events reporting of ACT, some limitation 
however must be considered. Most of the interviews were 
conducted in the main local languages in the study area 
(Kasem and Nankani) and some people were engaged to 
transcribe and translate the recordings into English. It is 
possible that certain individuals could introduce some 
Page 7 of 8Chatio et al. Malar J  (2016) 15:125 
level of bias in few of the statements made in the local 
languages in trying to translate them into English, which 
could have affected the original meaning. To help allevi-
ate this, the transcripts were edited by the study team in 
order to make sure that the transcriptions and transla-
tions were properly done.
Discussion
The study presents reported side effects as are experi-
enced from using ACT to treat uncomplicated malaria 
using qualitative approach. Body weakness and dizziness 
are the most frequent side effects many of the patients 
reported. Majority of the patients who took artesunate-
amodiaquine and artemether-lumefantrine, respectively, 
reported to have experienced side effects such as body 
weakness, dizziness, itching and abdominal pain [5–14]. 
In this study however, views expressed are slightly differ-
ent because most patients attributed all the side effects 
to the use of artesunate-amodiaquine compared to other 
combinations.
According to Asante et  al., side effects such as head-
ache, inability for some patients to control the neck and 
tongue were reported by patients who used ACT [5]. 
These side effects have not been reported in this study. 
However, swollen testes was reported in this study as one 
of the side effects of ACT. It is possible that swollen tes-
tes may not be as a result of the use of ACT as reported 
by participants. It could be that this coincided with the 
use of the medication by the person and because of that it 
was attributed to it. It is possible that these differences in 
views on the side effects on the use of ACT could be as a 
result of differences in individual human system.
Patients are supposed to eat very well before using 
these medications. According to the study participants, 
patients’ inability to eat food before using the drugs made 
them to experience these side effects. When the artesu-
nate-amodiaquine was first introduced in Ghana, many 
patients who used it had several side effects because 
the components of the drug were very high [7]. Opin-
ions from patients who use artesunate-amodiaquine in 
this study suggested that the components are still high 
and that could be the reason why they are still experi-
encing these side effects. It is demonstrated that poor 
noncompliance to guidelines to the use of medications 
accounted for drug side effects [15]. The health profes-
sionals explained that some malaria patients only initiate 
treatment when the condition is severe and that this was 
responsible for some of the side effects and not necessar-
ily the ACT. They added that poly-pharmacy was com-
mon within the health system and that drug interaction 
was more likely to cause some of the side effects that the 
patients complain about. The health workers reported 
non-adherence to the dosing regimen as a significant 
contributor to side effects. They were particularly con-
cerned about overdosing by some patients.
In Ghana, the policy is that all patients are supposed to 
be well informed by prescribers and pharmacists on the 
possible side effect they are likely to experience from the 
use of ACT and the need for them to report. However, 
people are not being encouraged to report when they 
experience these side effects. This study solicited views 
from patients on the factors affecting adverse events 
reporting. Two broad factors were identified (health facil-
ity factors and patient factors) to be responsible for low 
reporting of adverse events. Earlier study reported that 
because of lack of knowledge, seventy-five percent (75) % 
of those who experienced side effects did not report to 
health workers [4].
Based on the views shared by participants, health work-
ers are not educating patients on the possible side effects 
they are likely to experience and the need to report them. 
The inability of health professionals to give the necessary 
health information to patients directly affects adverse 
events reporting [4]. The problem could be resolved if 
efforts are made by health workers who prescribe ACT 
to patients to provide the needed health educate on these 
drugs to them. Long waiting time at health facilities and 
negative health worker attitude discouraged patients 
from attending health facilities for health care [15, 16]. 
These were also mentioned as factors affecting effective 
side effects reporting in this study.
The fact that patients who previously reported side 
effects at the health facility and could not get any help 
from health workers has been reported to have negative 
effect on adverse events reporting. Patients are expected 
to be taken care of by health providers when they visit the 
health facility for medical care. It is, therefore, normal 
that when patients are not well looked after, they would 
not be encouraged to visit the health facility when they 
have similar health issues in future.
Generally, reports on adverse effects of drugs were 
rare within the health facilities. A few facilities, mostly 
the health centres, reported completing the adverse drug 
reporting form for a few cases. These facilities reported 
using feedback from the FDA, to observe patients who 
suffered particular side effects during subsequent treat-
ments, Most of the community health compounds had 
never documented any side effect and they did not have 
the appropriate forms to capture adverse events.
Conclusion
The key factors responsible for the inability of patients 
to report side effects from using ACT are lack of health 
education, attitude of some patients and the unpleasant 
behaviour of some health workers towards patients at the 
health facilities. Despite the fact that some level of health 
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education has been given to patients by health workers 
on the use of ACT and how to prevent malaria, there is 
a need for health workers to specifically educate patients 
on the side effects of ACT.
It is, therefore, recommended that intensive and con-
tinued education should be incorporated into the routine 
health care activities. Patients who have been given ACT 
should be informed and encouraged by health workers, 
pharmacists and chemical shop owners to quickly report 
any adverse events they would have experienced from 
using ACT. Also, patients who experience side effects 
should be properly taken care of at the health facility 
during review visits. If possible, a different consultation 
room should be created only for such purpose at the 
health facilities. This will encourage patients who experi-
ence side effects to report them.
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